Accelerating radioligand therapy development from discovery through IND-enabling studies.
Advancing a radioligand therapy candidate requires coordinated expertise across radiochemistry, biological characterization, molecular imaging, efficacy assessment, and dosimetry. Fragmented workflows can create unnecessary complexity, slow development, and make it more difficult to translate preclinical findings into meaningful decisions.
RLTPαth is Perceptive Discovery’s integrated approach to radioligand therapy development, connecting specialized scientific capabilities to support programs from radionuclide selection through IND submission.
What You’ll Learn
Download our RLTPαth flyer to explore:
- Radiochemistry and radionuclide selection: Radiolabeling development, optimization, purification, quality control, and stability testing.
- In vitro characterization: Binding, internalization, cytotoxicity, competition assays, and radioligand metabolism analysis.
- In vivo research: Oncology models, biodistribution, efficacy, tolerability, and quantitative imaging studies.
- Ex vivo analysis: High-sensitivity biodistribution, compound screening, and radiation toxicity assessment.
- Dosimetry and IND support: Human dose prediction, study design, and submission-ready reporting.
Discover how RLTPαth brings these capabilities together into a coordinated workflow designed to support data-driven decisions throughout radioligand therapy development.